PPT-DES-PCI was inferior to CABG for clinical outcomes at 5 years following revascularization

lesions The hazard was highest with CABG in the first 30 days with better outcomes with PCI between 30 days and 5 years outcomes were inferior with PCI compared with CABG CABG n 592. SS Jolly, JA . Cairns, . S . Yusuf, . B . Meeks, . J . Pogue, . MJ . Rokoss, . S . Kedev, . L . Thabane, . G . Stankovic. , . R . Moreno, . A . Gershlick, . S . Chowdhary, . S . Lavi, . K . Niemelä, . . c. oronary. . d. isease. . d. iagnosed. . at the . t. ime. . of . p. rimary. . PCI for STEMI: . c. omplete. . r. evascularization. . v. ersus. . c. onservative. . s. trategy. . . PRAGUE . Susana G. Garcia MD. No Disclosure. Objectives. Review the current definition, risk factors, clinical impact and incidence of PMI. Describe the different clinical presentation of PMI and how this dictate the goal and approach to diagnosis and treatment of PMI. –. DEFINE-FLAIR . Justin E Davies, MD, . PhD on behalf of the DEFINE-FLAIR investigators. Hammersmith Hospital, . Imperial College London. F. unctional . L. esion . A. ssessment of . I. ntermediate stenosis to guide . Percutaneous. Coronary Interventions in . Washington State. Chris L. Bryson, MD, MS, COAP Medical Director. Steven M. Bradley, MD; Charles Maynard, PhD. VA Puget Sound Healthcare System and University of Washington. vs. FFR-guided . Coronary Intervention . –. . iFR. -SWEDEHEART. Matthias Götberg, . MD, . PhD. Department of Cardiology, Lund University. Skane. University Hospital. Lund, Sweden. Disclosures. Volcano/Philips: Unrestricted grant to fund . bypass grafting in treatment of unprotected left . main stenosis. Nordic–Baltic–British . left main . revascularisation study . (NOBLE. ). A . prospective, randomised, open-label. , non-inferiority trial. Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation. C. linical . O. utcomes . U. tilizing . R. evascularization and . Ag(?). gressive. Drug . E. valuation. In patients with STABLE coronary artery disease (CAD), what treatment should I pursue initially?. Lawrence J. Fine, MD, . DrPH. , . FAHA. Division . of Cardiovascular Sciences. NHLBI/NIH. November 16, . 2013. Disclosures: . None. SHAPE Symposium. When I was a glimmer in my parent’s eye the March of Dimes had a mission to eradicate polio . . 2021 ACC/AHA/SCAI Guideline of Coronary Artery Revascularization. Table 1. . Applying. . ACC/AHA Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care . Eric J. Velazquez, MD . on behalf of the STICH Investigators. April 4, 2011. STICH Financial Disclosures. Original Recipient Institution. Principal Investigator. Activity. Duke University Medical Center. vs.. . c. oronary artery bypass for multi-vessel disease: a meta-analysis. . Nirav C Patel MD, Jonathan M Hemli MD, Karthik Seetharam MD, Annapoorna Uttara BS, Derek R Brinster MD,. . Luigi Pirelli MD, Chad . moderator:. Jeremy Rock. President ● . RockIT. Group. Agenda. PCI Overview. Removing Card Data From Your Hotel. . Best Practices. Questions & Answers. PCI. . Overview. Presenters:. Mark Haley, . on behalf of the OPTIMUM Investigators. O. utcomes of . P. ercutaneous . Revasculariza. TI. on. for . M. anagement of . S. U. rgically. Ineligible Patients with . M. ultivessel or Left Main Coronary Artery Disease: Primary Results from the .